NCT07007312 2026-04-09
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
Clinical Trials
89 trialsNCT07223814 2026-04-06
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06578247 2026-03-31
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT07407140 2026-03-25
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT07486479 2026-03-20
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
NCT07132684 2026-03-02
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT07022678 2026-02-27
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Not yet recruiting
NCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT03182244 2026-02-06
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT05183035 2026-01-13
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC
Phase 3 Recruiting
NCT02421939 2025-12-04
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Phase 3 Completed
NCT01371981 2025-11-26
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07232134 2025-11-20
AML-DS-2025
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT03069352 2025-09-30
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie
Phase 3 Completed
NCT02521493 2025-08-01
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT03897127 2025-07-17
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
University of Ulm
Phase 3 Active not recruiting
NCT03765541 2025-04-10
DEXAML-03
University Hospital, Toulouse
Phase 3 Terminated
NCT05586074 2025-04-09
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT03507842 2025-03-17
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Asan Medical Center
Phase 3 Enrolling by invitation
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT05177731 2024-10-03
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
The First Affiliated Hospital of Soochow University
Phase 3 Active not recruiting
NCT02668653 2024-08-06
QuANTUM-First
Daiichi Sankyo
Phase 3 Completed
NCT03379727 2024-02-29
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis
Phase 3 Completed
NCT02013648 2024-02-23
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)
University of Ulm
Phase 3 Completed
NCT01497002 2024-01-31
AML2004
University of Leipzig
Phase 3 Completed
NCT05020665 2024-01-10
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio
Phase 3 Terminated
NCT06182592 2023-12-28
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3 Not yet recruiting
NCT00046930 2023-07-05
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00049517 2023-06-15
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT03416179 2023-04-21
BRIGHT AML1019
Pfizer
Phase 3 Completed
NCT01721876 2023-02-08
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Boehringer Ingelheim
Phase 3 Completed
NCT03504410 2023-02-08
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals
Phase 3 Terminated
NCT05382390 2022-05-19
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Phase 3 Unknown
NCT04509622 2022-05-05
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
AbbVie
Phase 3 Completed
NCT02927938 2022-04-21
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences
Phase 3 Terminated
NCT02545283 2022-01-11
MIRROS
Hoffmann-La Roche
Phase 3 Terminated
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04716114 2021-11-02
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT01246752 2021-10-29
AML
University Hospital Carl Gustav Carus
Phase 3 Terminated
NCT02724163 2021-10-08
Myechild01
University of Birmingham
Phase 3 Recruiting
NCT02298166 2021-10-06
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm
Phase 3 Terminated
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT00703820 2021-08-10
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT00372593 2021-03-24
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT01696084 2020-08-10
301
Jazz Pharmaceuticals
Phase 3 Completed